Steven M. Wahle, MD, has developed a stepwise process and takes an aggressive stance with insurers that deny certain imaging tests.
Dr. WahleWhen it comes to prior authorization, Steven M. Wahle, MD, has developed a stepwise process and takes an aggressive stance with insurers that deny certain imaging tests. “I’ve learned over the years how not to be mad or angry, but just very pointed that this is a patient care issue,” the Cedar Rapids, IA urologist said.
Dr. Wahle describes his successful technique in dealing with payers by phone as follows:
“Those are the pointed comments that I make,” Dr. Wahle said. “I’ve not been turned down. I’ve not had a denial.”UT
Subscribe to Urology Times to get monthly news from the leading news source for urologists.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
2 Clarke Drive
Cranbury, NJ 08512